CMS does not have long to finish the first phase of its proposed Part B drug price demonstration if it wants to stay on schedule to start it this fall, and some lobbyists expect the administration to publish the rule next month. Whenever it's published, lobbyists and consultants expect CMS to make at least some of the changes that congressional Democrats requested, such as strengthening the appeals process and exempting rural providers or drugs without substitutes. Talk on the campaign...